|
NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. |
|
|
Patents, Royalties, Other Intellectual Property - UpToDate |
|
|
Consulting or Advisory Role - Roche/Genentech |
Research Funding - Roche/Genentech (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - University of Chicago |
|
|
Employment - Orthopedic Surgery PC (I) |
Consulting or Advisory Role - Varian Medical Systems |
Research Funding - Varian Medical Systems |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Accuray |
Patents, Royalties, Other Intellectual Property - UpToDate |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Genomic Health; Qfix; Varian Medical Systems |